Increasing evidences show that immune response affects the reparative mechanisms in injured brain. Recently, we have demonstrated that CD4 þ T cells serve as negative modulators in neurogenesis after stroke, but the mechanistic detail remains unclear. Glucocorticoid-induced tumor necrosis factor (TNF) receptor (GITR), a multifaceted regulator of immunity belonging to the TNF receptor superfamily, is expressed on activated CD4 þ T cells. Herein, we show, by using a murine model of cortical infarction, that GITR triggering on CD4 þ T cells increases poststroke inflammation and decreases the number of neural stem/ progenitor cells induced by ischemia (iNSPCs). CD4
Brain injury induces acute inflammation, thereby exacerbating poststroke neuronal damage. [1] [2] [3] [4] Although central nervous system (CNS) is known for its limited reparative capacity, inflammation is a strong stimulus for reparative mechanisms including activation of neurogenesis. However, the latter results in low survival of newly generated neural stem cells. 5 These findings indicate the relevance of endogenous regulatory and/or environmental factors for survival and differentiation of neural stem cells.
In a murine model of cerebral ischemia, we have detected neural stem/progenitor cells induced by ischemia (ischemiainduced neural stem/progenitor cells; iNSPCs) in the poststroke cerebral cortex. 6 More recently, we have observed spontaneous accelerated repair in severe combined immunodeficient mice (SCID) compared with immunocompetent wild-type controls, 7 and have demonstrated that CD4 þ T cells serve as negative regulators in the survival of iNSPCs. 8 Together with previous reports supporting the importance of the role of T cells in regulating poststroke inflammation 1, 2, 9 and functional recovery, 1, 10, 11 these findings emphasize on the link between CD4
þ T cells and survival of iNSPCs. However, the mechanistic details and the subpopulation of CD4 þ T cells responsible for acting as negative regulators in CNS repair remain unclear.
Glucocorticoid-induced tumor necrosis factor (TNF) receptor (GITR)-related protein that was originally cloned in a glucocorticoid-treated hybridoma T-cell line 12 is a protein belonging to the TNF receptor superfamily. It is expressed at basal levels in responder resting T cells, with CD4 þ T cells including CD4 þ CD25 þ T cells (regulatory T cell, Treg) having a higher GITR expression than CD8 þ T cells. 13 When the T cells are activated, GITR is strongly upregulated in responder CD4 þ T cells. In this situation, the stimulatory effect of responder T cells was more activated 13, 14 and the suppressing effect of Treg was completely abrogated, 13 leading to a more enhanced immune/inflammatory response. 15 In the CNS, it has been reported that blocking of the GITR-GITR ligand (GITRL) interaction protected spinal cord injury from the inflammatory response, 16 whereas GITR triggering worsened experimental autoimmune encephalomyelitis while stimulating autoreactive CD4 þ T cells. 17 These observations lead us to hypothesize that GITR triggering on T cells may serve as a negative regulator for CNS repair after cerebral infarction.
In this study, we demonstrated for the first time that GITR triggering on T cells following ischemic stroke enhanced poststroke inflammation and cell death of iNSPCs. Administration of GITR-Fc fusion protein markedly suppressed these responses. In addition, GITR-triggered T cells directly induced apoptosis of iNSPCs in vitro. Our current results show that activated GITR þ T cells acted as negative modulators for CNS restoration, indicating that blockade of the GITR-GITRL interaction can be a novel strategy for treating ischemic stroke.
Results

Infiltration of CD4
þ GITR þ T cells into the ischemic cortex after stroke. Immunohistochemistry (Figures 1a-c) revealed that CD3 þ cells (T cells) appeared to infiltrate the ischemic region as early as 3 h after stroke ( Figure 1b ) and were observed continuously during the poststroke period (Figures 1d and g ). The T cells were rarely observed at nonischemic ipsilateral or contralateral cortex (Figure 1c ).
Most T cells in the ischemic region (B70% of T cells) were CD4 positive (Figures 1d-i), indicating that CD4
þ T cells predominantly infiltrate the poststroke cortex. However, GITR-positive cells were not found in the ischemic region at 6 h after stroke (Figure 2a) , whereas a number of T cells were detected at the same region (Figures 2b and c) . This indicates that GITR was not expressed in the infiltrated T cells at early poststroke period. GITR-expressing cells started to appear at 24 h after stroke and gradually increased in number. At 7 days post stroke, a number of CD3 þ T cells co-express GITR (Figures 2d-f) . Calculating the number of infiltrated T cells in serial brain sections revealed that B65% of CD4 þ T cells were GITR positive, indicating that GITR þ T cells predominantly occupied the subset of CD4 þ T cells at the late poststroke period. Semiquantitative analysis for the number of CD4 þ T or GITR þ cells in the ischemic region is shown in Figure 2g .
Predominant accumulation of CD4
þ GITR þ T cells at the ischemic cortex after stroke. To confirm the enhanced expression of GITR on CD4 þ T cells, we assessed the subset of T cells by FACS analysis using the cells extracted from the ischemic cortex 18 ( Figures 3a and b) . Consistent with the previous report, the brain extract contained substantial amount of mononuclear cells (Figure 3b ) and FACS analysis detected a distinct subset of lymphocytes that had infiltrated the ischemic cortex (Figures 3c-f) . We detected about 20% CD4 þ T cells extracted from the infarcted brain tissue. We at first gated CD3 þ cells and then analyzed CD25 to characterize the corresponding 
CD4
þ T cells. GITR was analyzed on CD3 þ CD4 þ cells. No significant upregulation of CD25 on T cells was observed at days 1 and 7 after stroke (Figures 3c and e: 4.61% at day 1 and 4.06% at day 7). However, the percentage of GITR þ T cells was increased from 6.17 to 86.50%, and the surface expression of GITR on CD4 þ T cells at day 7 was significantly increased compared with that at day 1 (from 13.90 to 68.37 in mean channel value; Figures 3d and f), indicating enhanced expression of GITR as an activation marker for CD4 þ T cells.
Effects of GITR triggering on cerebral infarction. Given that GITR triggering was involved in cerebral ischemic injury, we decided to examine whether stimulation or inhibition of GITR triggering affects cerebral infarction by using the same stroke model. Mice were treated with anti-GITR agonistic antibody (GITR-Ab: DTA-1), GITR-Fc fusion protein (blocking the GITR-GITRL interaction) or control IgG at 3 h and 3 days after stroke. The brain was then removed 30 days after stroke. The size of infarction in mice treated with GITR-Ab was apparently larger than that of mice treated with GITR-Fc ( Figure 4a ). Further analysis of the volume of each hemisphere based on brain sections demonstrated a significant decrease in the poststroke brain volume in GITR-Ab mice, and a significant increase in that of GITR-Fc mice, compared with control mice (Figure 4b ). These findings indicated that ischemic injury was enhanced by GITR triggering, while ameliorated by its blocking.
Effects of GITR triggering on poststroke inflammation. . We had until then attempted to determine how the triggering of GITR could affect poststroke inflammation. As several studies have reported that multiple cytokines modulate CNS inflammation, 2, 3, 19 the levels of IFN-g, TNF-a and IL-10 were analyzed using quantitative real-time PCR in mice 7 days after stroke. The alteration of mRNA levels of these cytokines within the ischemic region was confirmed (Figure 4c-e) . GITR-Ab treatment resulted in a significant elevation of IFN-g (Po0.05) and TNF-a (Po0.05) levels, and a significant decrease in the IL-10 level (Po0.01) compared with the control IgG treatment. In contrast, treatment with GITR-Fc showed a significant decrease in IFN-g (Po0.01) and TNF-a levels (Po0.05), and a significant increase in IL-10 level (Po0.01) compared with the control. These data indicated that GITR triggering largely affected cerebral ischemic injury by changing the level of poststroke inflammation (enhancing proinflammatory cytokines and suppressing anti-inflammatory cytokines). Effects of GITR triggering on survival/death of neural stem/progenitor cells. Inflammation is known not only as a deteriorated factor of cerebral injury but also as a strong stimulator of neurogenesis. As the current study has proved that GITR triggering can regulate the inflammatory response, 15, 17 we assessed the GITR-GITRL interaction, which may contribute to neurogenesis in the infarction area. Because we had previously showed that iNSPCs could contribute to poststroke neurogenesis and that cortical neurogenesis is related to the development of the iNSPCs, 8, 20, 21 the effects of GITR-Ab or GITR-Fc on survival/death of iNSPCs were investigated by using immunohistochemistry for nestin and active caspase-3 on the ischemic brain sections. The nestin-positive iNSPCs were observed at the border of the infarction as well as in the ischemic core 7 days after stroke (see Supplementary Figure  1B , red, nestin) as described. 6, 8, 20 Control IgG-treated mice appeared to have abundant nestin and active caspase- .05, GITR-Fc versus control IgG). These findings indicate that GITR triggering induced, whereas its blocking suppressed, apoptosis of iNSPCs.
To provide further support for our hypothesis that GITR triggering participates in iNSPC-death/survival, expressions of nestin and Sox2 (SRY (sex determining region Y)-box 2), neural stem cells markers, 22 were assessed by immunohistochemistry ( þ T cells by ligation of GITR has been reported previously, 17 and we also confirmed enhanced expression of GITR on CD4 þ T cells by GITR-Ab (DTA-1; see Figure 8d ; lanes 3, 4). Initially, to confirm infiltration of the administered T cells into the ischemic area, T cells extracted from the green fluorescence proteintransgenic (GFP-Tg) mice were injected into SCID mice 2 days after stroke as described previously. 7, 20 Five days after administering, the GFP-positive T cells migrated selectively into the infarction area of the poststroke brain (Supplementary Figure 2) . Next, we injected T cells of CB-17 mice (either stimulated or non-stimulated by GITR-Ab) as described above, and examined the expressions of nestin/ Sox2 double-labeled cells 5 days after injection by immunohistochemistry (Figures 6a-d ). In accordance with our previous report, 8 poststroke SCID mice with PBS injection (control) expressed a greater number of nestin/ Sox2-positive iNSPCs than CB-17 mice (compare Figure 6d with Figure 5h ). The administration of GITR-stimulated T cells significantly decreased the number of nestin/Sox2 cells (Figures 6b and d ; Po0.01), whereas non-stimulated T cells had no significant effect (Figures 6c and d) . These findings were confirmed by conventional RT-PCR analysis (Figure 6e ). Relative expressions of both nestin and Sox2 were attenuated by administration of GITR-stimulated T cells but not by non-stimulated T cells (Figures 6f and g ). The proliferation of iNSPCs was also evaluated by labeling of nestin-positive cells with bromodeoxyuridine (BrdU), as per a previous report. 8 GITR-stimulated T cells significantly decreased the number of BrdU-labeled nestin-positive cells compared with PBS treatment as a control (Figures 6i and k ; Po0.01), whereas non-stimulated T cells had no significant effect (Figures 6j and k) . These findings indicate that GITRtriggered, activated CD4 þ T cells, but not non-stimulated T cells, affect survival/death of iNSPCs after stroke.
In vitro effects of TNF-a and Fas ligand on apoptosis of neural stem/progenitor cells. To determine how activated CD4 þ T cells ligated by GITR affect survival/death of iNSPCs, a cell death assay was performed using cultured neurospheres consisting of iNSPCs (Figure 7a) . It is well known that some neural stem/progenitor cells undergo 23 and Fas. 8 Consistent with these studies, we confirmed expression of TNFR-1 ( Figure 7b ) and Fas (Figure 7c ) on iNSPC neurospheres. The neurospheres were incubated with Dulbecco's modified Eagle's medium (DMEM) containing TNF-a or agonistic Fas antibody (Jo-2) for 24 h, and their apoptosis was analyzed by Annexin V staining and active caspase-3 assay. As expected, TNF-a induced apoptosis of neurosphere cells (Figure 7d ; green: Annexin V, red: PE). The activity of caspase-3 in the apoptotic neurosphere was increased dose dependently by TNF-a (Figure 7g ). Jo-2 also induced apoptosis of neurospheres (Figure 7e) , with a significant increase in caspase-3 activity (Figure 7h ). Because iNSPCs neurosphere do not express GITR (Figure 7f) , it is not likely that GITR signaling regulates death-receptor-induced apoptosis directly in iNSPCs. Accordingly, neither GITR-Ab nor GITR-Fc activated caspase-3 on the neurospheres (Figure 7i ). These findings suggest that the death signaling pathway may be stimulated either directly or indirectly by activated CD4 þ T cells ligated by GITR. Moreover, these results also prove that the triggering of GITR directly have no effect on apoptosis of iNSPCs.
Effect of GITR-stimulated Gld-T cells on survival/death of neural stem/progenitor cells. To assess the action of activated T cells, neurospheres were incubated with T cells (either GITR stimulated or non-stimulated) for 24 h (Figures 8a and b) . Consistent with previous studies, 16, 24 T cells stimulated by GITR-Ab showed upregulation of Fas ligand (FasL) expression (Figures 8c and d; lanes 3 and 4) as well as GITR expression (Figure 8d; lanes 3 and 4) . Annexin V staining showed that neurospheres coincubated with GITR-stimulated T cells underwent apoptosis (Figure 8a ), but those with non-stimulated T cells did not (Figure 8b ). This result strongly suggested a role of FasL expressed on T cells in the iNSPCs apoptosis. Because nestin-positive iNSPCs were frequently observed in close association with endothelial cells 20, 21 and CD4 þ T cells (Supplementary Figure 3) in the poststroke brain, it is highly possible that activated T cells induce apoptosis of iNSPCs by cell to cell interactions.
To confirm this hypothesis in vivo, we administered T cells from the FasL-deficient (generalized lymphoproliferative disorder ¼ spontaneous mutation in the Fas ligand gene; gld) mice, 25 stimulated by GITR-Ab, to poststroke SCID mice and analyzed the expression of nestin and Sox2 in the postischemic area by conventional RT-PCR. As gld-T cells stimulated by GITR-Ab showed enhanced GITR expression compared with non-stimulated gld-T cells similar to T cells from wild-type mice (Figure 8d; lanes 1 and 2, Figure 8f ), the injected T cells were considered to be activated without 
Discussion
This study clearly demonstrated a key role of GITR triggering in regulation of neurogenesis after stroke, thereby delineating the contribution of activated T cells expressing GITR to the survival of neural stem/progenitor cells in the poststroke cortex. Because a subset of CD4 þ T cells mainly expresses GITR after stroke, it is likely that activated CD4 1 and 3; f) . The group of GITR-stimulated T cells from C57B/6 only significantly upregulated FasL (d and e). (a) Scale bar: 100 mm. (e and f) n ¼ 5 for each experimental group. **Po0.01 versus Gld-T cell groups or non-stimulated T (GITR-Ab(À)/C57B/ 6-T) cell group. Expression of nestin or Sox2 detected by conventional RT-PCR in the ischemic cortex of SCID mice 7 days after stroke was not affected by administration of Gld-T cells stimulated by GITR-Ab (g: first versus second lanes; h and i), although it was significantly decreased after treatment with wild-type (C57B/6) T cells stimulated by GITR-Ab (g: third versus fourth lanes; h and i). The relative expression of nestin or Sox2 was significantly suppressed only in the case of mice administered with FasLexpressed T cells stimulated by GITR-Ab. (h and i) n ¼ 5 for each experimental group. **Po0.01 versus Gld-T cell groups, GITR(À)/C57B/6-T-cell group or PBS group. No significant difference was found among the other groups with the latter serving as negative regulators for CNS repair after cerebral infarction.
GITR was originally cloned from a glucocorticoid-treated hybridoma T-cell line as a TNF-receptor-like molecule induced by glucocorticoid-sensitive T cells. 12 GITR is now considered to be upregulated in T cells by T-cell receptor (TCR)-mediated activation. 26 As GITR-expressing T cells are resistant to glucocorticoid-induced cell death, it has been proposed that GITR, in conjunction with other TCR-induced factors, protects T cells from apoptosis. 26 In fact, GITR can be upregulated by viral infection 27 or acute lung inflammation. 15 In the present study, we have demonstrated for the first time that GITR is upregulated in T cells by ischemic insult to the brain, although previous reports have shown the role of GITR in ischemic damage on the kidney or the intestine. 28, 29 Consistent with our previous study, 8 CD4 þ T cells predominantly migrated to the infarcted brain after stroke. The high number of GITR þ CD4 þ T cells suggested that activated T-cell proliferation contributed to the poststroke inflammatory response. GITR has been reported to enhance the secretion of proinflammatory cytokines, such as IL-2 and IFN-g, from GITR þ T cells. 30 In contrast, GITR triggering on CD4 þ CD25 þ Treg completely abrogates the suppressing effect of Treg, 13 which normally secrete anti-inflammatory cytokines such as IL-10. 31 Thus, we suggest that upregulation of the GITR expression in the brain can aggravate T-cellmediated poststroke inflammation. The present study demonstrated that GITR triggering in poststroke mice enhanced, and its blocking ameliorated the poststroke inflammatory response as indicated by modulation of cytokines, such as IFN-g, TNF-a and IL-10. These data suggest that T-cellmediated poststroke inflammation can be modulated by the immune response deriving from GITR-GITRL interaction.
It is well known that cerebral injury induces a disturbance of the normally well-balanced interplay between the immune system and the CNS. 32 This process results in homeostatic signals being sent to various sites in the body through pathways of neuroimmunomodulation, including hypothalamic-pituitaryadrenal (HPA) axis. Activation of the HPA axis results in the production of glucocorticoid hormones. Although glucocorticoid does prevent inflammation by suppressing production of many proinflammatory mediators, including cytokines such as IL-1b and TNF-a, it also induces apoptosis in immature and mature T lymphocytes. 33 The latter may in turn lead to secondary immunodeficiency. 32 Alternatively, surviving T cells that are resistant to glucocorticoid stress express GITR and may contribute to the aggravation of inflammation.
Inflammation in neural tissue has long been suspected to have a role in stroke. Immune influence on adult neural stem cell regulation and function has also received much attention. Although the details of immune signaling in the CNS are not known, the impact of inflammatory signaling on adult neurogenesis is known to be focused on the activation of microglia as a source of proinflammatory cytokines, such as TNF-a, IL-6 and IL-1b. We and others 34 have proved that neural stem cells undergo apoptosis by TNF-a in vitro, suggesting that TNF-a has a negative effect on poststroke neurogenesis. Recent publication has revealed that GITR and GITRL are functionally expressed on brain microglia, and that the stimulation of GITRL can induce inflammatory activation of microglia. 35 However, as iNSPCs never expressed GITR, it is more likely that microglia contribute to iNSPC cell death indirectly via TNF-a, which is secreted from the activated microglia. We also propose that IFN-g produced by activated GITR þ T cells stimulates microglia production of high levels of TNF-a to induce apoptosis of iNSPCs through TNFR-1. It also has been reported that TNF-related apoptosis-inducing ligand (TRAIL) has an important role in developing CNS injury, and that anti-TRAIL treatment prevents GITR expression induced by spinal cord injury. 36 As GITR-deficient mice showed attenuated TRAIL expression after SCI, blocking the GITR-GITRL interaction by GITR-Fc protein may protect from the inflammatory response via TRAIL-activated pathways.
In addition to cytokine effects on neurogenesis, we also proposed the Fas-mediated pathway that affects poststroke neurogenesis, as another target of immune signaling. Our previous study 8 had shown that Fas-positive iNSPCs underwent apoptosis in the poststroke cortex. The current study confirmed that GITR þ T cells expressing FasL triggered apoptosis of iNSPC in vitro and reduced the expression of nestin and Sox2 in the poststroke brain. These findings suggest that activated T cells act on Fas-expressing iNSPCs via cell to cell interactions in the poststroke brain, although it is very difficult to prove the functional contact between iNSPCs and Fas-expressing T cells in vivo. As nestin-positive iNSPCs are in close association with endothelial cells 20, 21 where CD4 þ T cells are infiltrated (Supplementary Figure 3) , it is possible that activated T cells are in contact with neural stem/ progenitor cells when the endothelial cells are damaged by ischemic insult. Although another system that activates neurogenesis through soluble FasL and Fas receptor in conventional neurogenic regions has been previously reported, 37 the current study may prove that the membranebound FasL expressed on T cells is essential for Fas-induced apoptosis. 38 Recent study has proposed the contribution of Tregs in prevention of secondary infarct growth. 2, 4 Because IL-10 signaling was mainly produced by CD4 þ CD25 þ Tregs and proinflammatory cytokines were downregulated in brains of IL-10 transgenic mice, Tregs apparently contribute to the anti-inflammatory system after stroke. Although GITR þ T cells are known to belong to Tregs, a recent study has emphasized that GITR is a marker for activated effector T cells. 39 The CD4 þ CD25 À T-cell-derived GITR þ cells (GITR þ non-Treg) are also known to activate self-reactive T cells by attenuating the function of Tregs, 13 indicating that they may harm the living cells by eliciting autoimmunity. 13, 24 We demonstrated in the current study that blocking the GITR-GITRL interaction by GITR-Fc protein increased IL-10 expression in the poststroke cortex, suggesting that blocking such interactions enhanced Treg function as well as inhibition of effector T cell function. On the basis of these findings, the present study suggests that the novel therapies for stroke may ultimately include GITRtargeted manipulation of immune signaling.
Materials and Methods
All procedures were carried out under auspices of the Animal Care Committee of Hyogo College of Medicine, and were in accordance with the criteria outlined in the 'Guide for the Care and Use of Laboratory Animals' prepared by the National Academy of Science. Quantitative analyses were conducted by investigators who were blinded to the experimental protocol and identity of the samples under study.
Induction of focal cerebral ischemia. Male, 5-to 7-week-old, CB17/ Icr þ / þ Jcl mice (CB-17 mice; Clea Japan Inc., Tokyo, Japan) and CB-17/Icr scid/scid Jcl mice (SCID mice; CLEA Japan Inc.) were subjected to cerebral ischemia. Permanent focal cerebral ischemia was produced by ligation and disconnection of the distal portion of the left middle cerebral artery (MCA), as described in a previous study. In brief, the left MCA was isolated, electrocauterized and disconnected just distal to its crossing of the olfactory tract (distal M1 portion) under halothane inhalation. The infarcted area in mice of this background has been shown to be highly reproducible and limited to the ipsilateral cerebral cortex. Permanent MCA occlusion (MCO) is achieved by coagulating the vessel. In sham-operated mice, arteries were visualized but not coagulated.
Immunohistochemistry. To histochemically analyze the infarcted cortex, mice were deeply anesthetized with sodium pentobarbital and perfused transcardially with 4% paraformaldehyde. Brains were then removed, and coronal sections (14 mm) were stained with mouse antibodies against nestin (Millipore, Billerica, MA, USA; 1/100), Sox2 (Millipore; 1/100), NeuN (Millipore; 1/200), rabbit antibodies against caspase-3 active (R&D systems, Minneapolis, MN, USA; 1/100), CD3 (AnaSpec, San Jose, CA, USA; 1/100), CD31 (Santa Cruz Biotechnology, Santa Cruz, CA, USA; 1/100), rat antibody against CD4 (Biolegend, San Diego, CA, USA; 1/100) and GITR (eBioscience, San Diego, CA, USA; 1/100). As secondary antibodies, Alexa Fluor 488 or Alexa Fluor 555 goat anti-mouse, -rabbit or -rat IgG (Invitrogen, Carlsbad, CA, USA; 1/500) was used. Cell nuclei were stained with 4 0 , 6-diamino-2-phenylindole ( DAPI, Kirkegaard & Perry Laboratories, Gaithersburg, MD, USA; 1/500). The number of nestin and Sox2 double-positive cells at the border of infarctions, including the infarcted and peri-infarcted areas (0.5 mm in width), was counted under a laser microscope (Olympus Corporation, Tokyo, Japan).
To perform quantitative analysis of T cells, all CD3-, CD4-or CD3-GITRdouble-positive cells within the infarcted area were counted in the brain sections obtained from CB-17 mice at 3 h, 6 h, 24 h, 3 days and 7 days after stroke. Furthermore, active caspase-3 and nestin double-positive cells within the infarcted area were counted in the brain sections at 3 days after stroke. To investigate cell proliferation at 7 days after stroke, BrdU (Sigma-Aldrich Corporation, St. Louis, MO, USA; 50 mg/kg) was administered 6 h before fixation. Tissue was pretreated with 2N HCl for 30 min at 371C and 0.1 M boric acid (pH 8.5) for 10 min at room temperature, and then stained with antibody against BrdU. Next, the number of positive cells for each marker was determined using modified Image J (National Institute of Mental Health, Bethesda, MD, USA) as per a previous report. 8 Results were expressed as the number of cells/mm 2 .
The expression of Fas and TNFR-1 for neurosphere. To study the expression of Fas and TNFR-1in the neurosphere in vitro, immunochemistry was performed with rabbit antibody against Fas (Wako Pure Chemical Industries, Osaka, Japan; 1/100) or TNFR-1 (Santa Cruz Biotechnology; 1/100). As secondary antibodies, Alexa Fluor 488 or Alexa Fluor 555 goat anti-mouse IgG (Invitrogen; 1/500) was used. Cell nuclei were stained with DAPI (Kirkegaard & Perry Laboratories; 1/500).
Measurement of involution of the ipsilateral cerebral hemisphere volume. Thirty days after stroke, mice were perfused transcardially with 4% paraformaldehyde, brains were removed and coronal sections (14 mm) were stained with mouse antibodies against NeuN, followed by reaction with biotinylated goat anti-mouse IgG (Chemicon, Temecula, CA, USA; 1/500), ABC Elite reagent (Vector Laboratories, Burlingame, CA, USA) and DAB (Sigma-Aldrich Corporation) as chromogen. The area of the ipsilateral and contralateral cerebral hemisphere occupied by the neuronal markers, NeuN and MAP2, was calculated using Image J. 8 The ipsilateral and contralateral cerebral hemisphere volume was calculated by integrating the coronally oriented ipsilateral and contralateral cerebral hemisphere area as described previously. 8 Involution of the ipsilateral cerebral hemisphere volume was calculated as (ipsilateral/contralateral cerebral hemisphere volume).
FACS analysis of infiltrated lymphocytes into the ischemic brain. Animals were killed 1 or 7 days after MCO. The ischemic area of the brain was isolated. Tissues from the four operated mice were incubated with RPMI1640 (Invitrogen), containing 1 mg/ml collagenase (Wako Pure Chemical Industries) and 0.1 mg/ml DNAse I (Thermo Fisher Scientific, Waltham, MA, USA), and pressed through a 40-mm cell strainer 18 (BD Biosciences, Franklin Lakes, NJ, USA). The mononuclear cells were separated by Ficoll-paque plus (GE Healthcare, Piscataway, NJ, USA) centrifugation, and labeled with antibody cocktails (Per CP-CD3 (BD Biosciences), FITC-CD4 (eBioscience), PE-GITR (BD Biosciences) and APC-CD25 (eBioscience)). Rat IgG2a (eBioscience) was used as control isotype staining. The analysis of cells was performed by four-color flow cytometry on a FACSCalibur (BD Biosciences) using CELLQuest Software (BD Biosciences).
RNA isolation and PCR reaction. Total RNA was isolated from the cerebral cortex of the infarcted area using ISOGEN (Nippon gene, Tokyo, Japan), and was treated using Turbo DNA-free kit (Applied Biosystems, Foster city, CA, USA) in accordance with the manufacturer's protocol.
Quantity and quality of the isolated RNA was tested by using a Nanodrop 1000 (Thermo Fisher Scientific).
Quantitative real-time PCR was performed using TaqMan Gene Expression Assays and the ABI PRISM 7900HT Sequence Detection System (Applied Biosystems) with Real-time PCR Master Mix (Toyobo, Osaka, Japan). Three replicates were run for each sample in a 384-well format plate. TaqMan Gene Expression Assays IDs were described as follows. IFN-g: Mm01168134_m1, TNF-g: Mm00443258_m1, IL-10: Mm01288386_m1 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH): Mm99999915_g1.
Conventional RT-PCR was performed using a PC-708 (Astec, Fukuoka, Japan) with Super Script III One step (Invitrogen). cDNA was amplified under the following conditions: 15 s at 941C, 30 s at 601C and 1 min at 681C (35 cycles). PCR products were analyzed by electrophoresis using Mupid (Advance, Tokyo, Japan). The band intensity was determined with a LAS-1000 densitometer (Fuji Film, Tokyo, Japan). Primer sequences were as follows:
nestin, forward Preparation of induced neural stem/progenitor cells. As described previously, 6 tissue from the ischemic cortex was mechanically dissociated by passage through 23-and 27-gauge needles to prepare a single-cell suspension. The resulting cell suspensions were incubated in a medium promoting formation of neurosphere-like clusters. Cells were incubated in tissue culture dishes (60 mm) with DMEM/F12 (Invitrogen) containing epidermal growth factor (EGF; Peprotech, Rocky Hill, NJ, USA; 20 ng/ml) and fibroblast growth factor-basic (FGF-2; Peprotech; 20 ng/ml). On day 7 after incubation, neurosphere-like cell clusters (primary spheres) were formed and were reseeded at a density of 10-15 neurospheres/well in 12-well low-binding plates.
Induction of apoptosis of neural stem/progenitor cells. To study the effect of TNF-a-or Fas-mediated signaling in vitro, neurospheres were incubated with TNF-a (R&D systems; 20 mg/ml and 100 mg/ml) or agonistic antiFas (Jo-2; BD Biosciences; 1 mg/ml) containing cycloheximide (CHZ; Sigma-Aldrich Corporation; 1 mg/ml), 40 agonistic anti-GITR (DTA-1; 10 mg/ml) or GITR-Fc fusion protein (6.25 mg/ml, Alexis Corporation, Lausen, Switzerland) in DMEM/F12 (Invitrogen) for 24 h. Next, the activity of caspase-3 was examined using a caspase-3 assay kit (Sigma-Aldrich Corporation) according to the manufacturer's protocol. Briefly, neurospheres were homogenized in lysis buffer and centrifuged at 20 000 g for 15 min. Supernatants were mixed with assay buffer and caspase-3 substrate. Absorbance at 405 nm was measured, and caspase-3 activity was calculated (n ¼ 3, in each group) using a spectrophotometer (Beckman Coulter Inc., Brea, CA, USA). Caspase-3 activity was correlated with the protein concentration, which was determined by the DC protein assay (Lowry method; Bio-rad Laboratories Inc., Hercules, CA, USA). To confirm the cells undergoing apoptosis, neurospheres incubated with these reagents were stained with Annexin V (BD Biosciences), and were observed under a confocal laser scanning microscope (Carl Zeiss International, Jena, Germany).
